CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
olopatadinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00609128
NCT00609128N/ACompleted
CompareCT.gov

Expression of Inflammatory Mediators in Allergic Conjunctivitis

University of Wisconsin, Madison·interventional·Posted Feb 6, 2008·Updated Sep 20, 2018

In Brief

A clinical study evaluating olopatadine for Allergic Conjunctivitis. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
CollaboratorsNational Eye Institute (NEI)

Timeline

N/ACompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2008
Enrollment StartSep 1, 2000
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 18.4 years ago

Interventions

olopatadinedrug

olopatadine one drop in one eye for one week